Next Article in Journal
COVID-19: The Ethno-Geographic Perspective of Differential Immunity
Previous Article in Journal
Validity and Reliability of the COVID-19 Knowledge, Attitude and Behavior Scale
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 2
10.3390/vaccines11020318
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models

by
Nicole Roth
1,
Janina Gergen
1,
Kristina Kovacikova
1,
Stefan O. Mueller
1,
Lorenz Ulrich
2,
Jacob Schön
2,
Nico Joel Halwe
2,
Charlie Fricke
3,
Björn Corleis
3,
Anca Dorhoi
3,
Donata Hoffmann
2,
Martin Beer
2,
Domenico Maione
4,
Benjamin Petsch
1,† and
Susanne Rauch
1,*,†
1
CureVac SE, 72076 Tübingen, Germany
2
Institute of Diagnostic Virology, Friedrich Loeffler Institut, 17493 Griefswald-Insel Riems, Germany
3
Institute of Immunology, Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany
4
GSK, 53100 Siena, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2023, 11(2), 318; https://doi.org/10.3390/vaccines11020318
Submission received: 4 January 2023 / Revised: 27 January 2023 / Accepted: 28 January 2023 / Published: 31 January 2023
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Review Reports Versions Notes

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and its subvariants (BA.2, BA.4, BA.5) represented the most commonly circulating variants of concern (VOC) in the coronavirus disease 2019 (COVID-19) pandemic in 2022. Despite high vaccination rates with approved SARS-CoV-2 vaccines encoding the ancestral spike (S) protein, these Omicron subvariants have collectively resulted in increased viral transmission and disease incidence. This necessitates the development and characterization of vaccines incorporating later emerging S proteins to enhance protection against VOC. In this context, bivalent vaccine formulations may induce broad protection against VOC and potential future SARS-CoV-2 variants. Here, we report preclinical data for a lipid nanoparticle (LNP)-formulated RNActive® N1-methylpseudouridine (N1mΨ) modified mRNA vaccine (CV0501) based on our second-generation SARS-CoV-2 vaccine CV2CoV, encoding the S protein of Omicron BA.1. The immunogenicity of CV0501, alone or in combination with a corresponding vaccine encoding the ancestral S protein (ancestral N1mΨ), was first measured in dose-response and booster immunization studies performed in Wistar rats. Both monovalent CV0501 and bivalent CV0501/ancestral N1mΨ immunization induced robust neutralizing antibody titers against the BA.1, BA.2 and BA.5 Omicron subvariants, in addition to other SARS-CoV-2 variants in a booster immunization study. The protective efficacy of monovalent CV0501 against live SARS-CoV-2 BA.2 infection was then assessed in hamsters. Monovalent CV0501 significantly reduced SARS-CoV-2 BA.2 viral loads in the airways, demonstrating protection induced by CV0501 vaccination. CV0501 has now advanced into human Phase 1 clinical trials (ClinicalTrials.gov Identifier: NCT05477186).
Keywords: COVID-19 variant; SARS-CoV-2; mRNA vaccine; virus neutralizing antibody titer COVID-19 variant; SARS-CoV-2; mRNA vaccine; virus neutralizing antibody titer

Share and Cite

MDPI and ACS Style

Roth, N.; Gergen, J.; Kovacikova, K.; Mueller, S.O.; Ulrich, L.; Schön, J.; Halwe, N.J.; Fricke, C.; Corleis, B.; Dorhoi, A.; et al. Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. Vaccines 2023, 11, 318. https://doi.org/10.3390/vaccines11020318

AMA Style

Roth N, Gergen J, Kovacikova K, Mueller SO, Ulrich L, Schön J, Halwe NJ, Fricke C, Corleis B, Dorhoi A, et al. Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. Vaccines. 2023; 11(2):318. https://doi.org/10.3390/vaccines11020318

Chicago/Turabian Style

Roth, Nicole, Janina Gergen, Kristina Kovacikova, Stefan O. Mueller, Lorenz Ulrich, Jacob Schön, Nico Joel Halwe, Charlie Fricke, Björn Corleis, Anca Dorhoi, and et al. 2023. "Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models" Vaccines 11, no. 2: 318. https://doi.org/10.3390/vaccines11020318

APA Style

Roth, N., Gergen, J., Kovacikova, K., Mueller, S. O., Ulrich, L., Schön, J., Halwe, N. J., Fricke, C., Corleis, B., Dorhoi, A., Hoffmann, D., Beer, M., Maione, D., Petsch, B., & Rauch, S. (2023). Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models. Vaccines, 11(2), 318. https://doi.org/10.3390/vaccines11020318

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop